Teva Jockeys For Advantage In Wake Of Tysabri Withdrawal, Avonex Warning
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tysabri withdrawal effects: GlaxoSmithKline, Antisense Therapeutics halt MS drug Phase II trials, citing identical mechanism of action. Teva, Serono, Schering jockey for advantage over Biogen Idec following additional reports of PML in Tysabri recipients, addition of Avonex liver warning